Yonglei Liu

Yonglei Liu

Auto-generated profile, based on publicly available information

Yonglei Liu

Department of Cardiology First Ward, Yidu Central Hospital of Weifang, Weifang, Shandong, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in Cellular Signalling
Verified
Journal Article
Closed access
YLYonglei Liu
Yonglei Liu
CMChuanzhong Mei
Chuanzhong Mei
LSLidong Sun
Lidong Sun
XLXin Li
Xin Li
MLMingzhu Liu
Mingzhu Liu
XZXiliang Zha
Xiliang Zha

1 January 2021 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
PDF file
PTPingPing Teng
PingPing Teng
YLYonglei Liu
Yonglei Liu
MZMeng Zhang
Meng Zhang
WJWanli Ji
Wanli Ji
Atherosclerosis (AS) is a common vascular disease with great harm. The current study examined the expression pattern of miR-18a-5p in AS patients, and explored its clinical values. 110 AS patients and 68 healthy controls were collected clinically, and the expression pattern of miR-18a-5p in the serum of AS patients was detected using qRT-PCR. All AS patients were followed up for five years to record the adverse cardiovascular events. ROC and Kaplan-Meier (K-M) curve were plotted to assess the diagnostic ability. The multiple Cox regression analysis was performed for independent influencing factors analysis. MiR-18a-5p was at high expression in AS patients, and showed positive correlation with the CIMT value (r = 0.789, P < .001). ROC curve suggested the high diagnostic value of serum miR-18a-5p for AS, with the AUC of 0.894. The diagnostic specificity and sensitivity were 86.8% and 79.1%, respectively. K-M plot demonstrated that cases with high miR-18a-5p levels were more likely to suffer from cardiovascular events, and it is an independent influence factor for the poor clinical outcome. Serum miR-18a-5p serves as a promising biomarker for AS diagnosis, and is related to the occurrence of adverse cardiovascular events.